Back to companies

NGM Biopharmaceuticals Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

NGM Biopharmaceuticals Inc (NGM Bio), a subsidiary of NGM Bio Holdings Inc, is a biopharmaceutical company that discovers and develops novel medicines to address unmet medical needs. The company’s pipeline products include NGM707 + pembrolizumab treats advanced solid tumors; NGM120 targets hyperemesis gravidarum and aldafermin for primary sclerosing cholangitis. The company’s biologic platform incorporates multiple technologies to generate and screen monoclonal antibodies. It operates in the US, the UK and Australia. GM Bio is headquartered in San Francisco, California, the US.

 Gain a 360-degree view of NGM Biopharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of NGM Biopharmaceuticals Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address 333 Oyster Point Boulevard, San Francisco, California, 94080
Website www.ngmbio.com
Telephone 1 650 2435555
No of Employees 138
Industry Pharmaceuticals and Healthcare
Revenue (2023) $4.4M
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

NGM Biopharmaceuticals Inc premium industry data and analytics

40+

Catalyst Calendar

Proactively evaluate NGM Biopharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Clinical Trials

Determine NGM Biopharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of NGM Biopharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

9

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

7

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on NGM Biopharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Pipeline
NGM707 + Pembrolizumab: Advanced Solid Tumors
NGM120: Hyperemesis Gravidarum, Cancer Cachexia
XYZ
XYZ
XYZ
Understand NGM Biopharmaceuticals Inc portfolio and identify potential areas for collaboration Understand NGM Biopharmaceuticals Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters NGM Biopharmaceuticals Inc AbbVie Inc Madrigal Pharmaceuticals Inc 89bio Inc Akero Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Francisco North Chicago West Conshohocken San Francisco South San Francisco
State/Province California Illinois Pennsylvania California California
No. of Employees 138 57,000 915 93 74
Entity Type Private Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Executives
Name Position Board Since Age
William J. Rieflin Chairman Executive Board 2022 -
Diana Peng Bockus Chief Executive Officer Senior Management 2025 -
Wendy Yeh, M.D. Chief Medical Officer Senior Management 2025 -
Victoria Leitman, Ph.D Executive Director - Chemistry, Manufacturing, and Controls Project Management Senior Management 2019 -
Tianny Szeto Vice President - Finance Senior Management 2019 -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into NGM Biopharmaceuticals Inc key executives to enhance your sales strategy Gain insight into NGM Biopharmaceuticals Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?